Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-107618
Filing Date
2025-08-13
Accepted
2025-08-13 07:03:32
Documents
81
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q spry-20250630.htm   iXBRL 10-Q 3120443
2 EX-10.1 spry-ex10_1.htm EX-10.1 431180
3 EX-10.3 spry-ex10_3.htm EX-10.3 19702
4 EX-31.1 spry-ex31_1.htm EX-31.1 16781
5 EX-31.2 spry-ex31_2.htm EX-31.2 16755
6 EX-32.1 spry-ex32_1.htm EX-32.1 21013
7 GRAPHIC img77826477_0.jpg GRAPHIC 484952
  Complete submission text file 0000950170-25-107618.txt   13003427

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT spry-20250630.xsd EX-101.SCH 1369455
84 EXTRACTED XBRL INSTANCE DOCUMENT spry-20250630_htm.xml XML 2063477
Mailing Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130 858-771-9307
ARS Pharmaceuticals, Inc. (Filer) CIK: 0001671858 (see all company filings)

EIN.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39756 | Film No.: 251208953
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)